NCT07827001 · University of California, Irvine
PilotStudyAssessSafeActiveSurveillancApproachLocalThe Pa w/BrainMetsUndergoinCNSPenetratSystemicThe
What this study is about
This is a Pilot clinical trial determining the safety of an active surveillance approach to local therapy in subjects with brain metastases. These are subjects who are undergoing CNS-penetrating systemic therapy.
View original scientific description
This is a Pilot clinical trial determining the safety of an active surveillance approach to local therapy in subjects with brain metastases. These are subjects who are undergoing CNS-penetrating systemic therapy.
Primary outcome measures
Feasibility of Enrolling Patients
Time frame: 1 year
Feasibility of enrolling patients as measured by percentage of patients enrolled compared to the anticipated study accrual.
Feasibility of completing required surveillance imaging
Time frame: 1 year
Feasibility of completing required surveillance imaging as measured by percentage of enrolled patients that complete surveillance imaging.
Feasibility of administering Cognitive Assessments
Time frame: 1 year
Feasibility of completing required Cognitive Assessments as measured by percentage of enrolled patients that complete QOL and Cognitive Assessments..
Feasibility of administering QOL Questionnaires
Time frame: 1 year
Feasibility of completing required Quality of Life (QOL) Questionnaires as measured by percentage of enrolled patients that complete QOL and Cognitive Assessments..
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- Patients must have histologically or cytologically confirmed metastatic non-hematologic malignancy.
- Patients must have at least one new or progressive brain metastasis that has not received prior local therapy (surgery or radiation therapy).
- Patients must have no active brain metastasis \>3cm in size.
- Leptomeningeal disease is permitted
- Patients with only non-measurable disease as defined by the RANO-BM criteria are permitted so long as the clinical determination of new or progressive disease has been made by the treating team.
- Patients must have no symptoms attributable to active brain metastases.
- At the time of enrollment, patients must be eligible for AND planning to begin a new line of systemic therapy with potential for CNS-efficacy. Determination of potential for CNS-efficacy will be determined based on the clinical judgement of the treating physicians. Patients must have had no prior exposure to the specific systemic therapy in question at the time of enrollment, though exposure to other medications from a similar class are acceptable at the discretion of the treating team.
- Patient must be planning to defer radiation therapy to trial medical therapy regardless of enrollment on trial.
- Must be age ≥ 18 years.
- Patients must be willing to complete MoCA and FACT-BR assessments (refer to section 4.4.1).
- Performance status: KPS performance status ≥50%.
- Life expectancy of ≥3 months.
- Ability to understand and willingness to sign a written informed consent document.
Exclusion criteria
- Patients who have only progressive growth of brain lesions that have previously been treated with surgery or radiation therapy.
- Patients with active symptomatic brain metastases.
- Patients requiring corticosteroids, anticonvulsants, or other palliative medications related to brain metastases.
- Patients with conditions that exclude them from undergoing magnetic resonance imaging.
Where
- Orange, California
Related conditions & keywords
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Sep 18, 2026 · Source of record for eligibility and locations